Abstract
The vanilloid receptor subunit 1, or transient receptor potential vanilloid 1 (TRPV1), integrates physical and chemical stimuli in the peripheral nervous system, playing a key role in inflammatory pain. Identification of potent TRPV1 antagonists is thus an important goal of current neuropharmacology. Herein, we describe the solid-phase synthesis of a series of indole-based peptoids (N-alkylglycines) and the biological activity of the peptoids as novel TRPV1 antagonists. The potency and selectivity of the compounds were determined by electrophysiological recordings in Xenopus oocytes. The most potent and selective noncompetitive TRPV1 antagonist of the series, compound 7, represents an interesting pharmacophoric structure for analgesic lead optimization.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Analgesics / chemical synthesis*
-
Analgesics / chemistry
-
Analgesics / pharmacology
-
Animals
-
Drug Design
-
In Vitro Techniques
-
Indoles / chemical synthesis*
-
Indoles / chemistry
-
Indoles / pharmacology
-
Oligopeptides / chemical synthesis*
-
Oligopeptides / chemistry
-
Oligopeptides / pharmacology
-
Oocytes / drug effects
-
Oocytes / physiology
-
Patch-Clamp Techniques
-
Peptoids / chemical synthesis*
-
Peptoids / chemistry
-
Peptoids / pharmacology
-
Rats
-
Structure-Activity Relationship
-
TRPV Cation Channels / antagonists & inhibitors*
-
TRPV Cation Channels / physiology
-
Xenopus
Substances
-
Analgesics
-
Indoles
-
Oligopeptides
-
Peptoids
-
TRPV Cation Channels
-
Trpv1 protein, rat
-
arginyl-(N-(2,4-dichlorophenethyl)glycyl)-N-(2-(indol-3-yl)ethyl)glycinamide